Migraine mechanism and management

Otolaryngologic Clinics of North America

Volumn 36, Issue 6, 2003, Pages 1063-1078

  Spierings, Egilius L H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ATENOLOL; BARBITURIC ACID DERIVATIVE; BISOPROLOL; CAFFEINE; CODEINE; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; FROVATRIPTAN; IBUPROFEN; INDOMETACIN; ISOMETHEPTENE; ISOMETHEPTENE MUCATE; KETOPROFEN; METOCLOPRAMIDE; METOPROLOL; NADOLOL; NAPROXEN; NARATRIPTAN; OPIATE; PARACETAMOL; PHENYLEPHRINE; RIZATRIPTAN; SUMATRIPTAN; SUPPOSITORY BASE; TIMOLOL; UNINDEXED DRUG; ZOLMITRIPTAN;

AEROSOL; ARTICLE; DISABILITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG HALF LIFE; EMPLOYMENT; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN RELATION; LIFESPAN; MIGRAINE; NAUSEA; NEUROPATHOLOGY; POPULATION; PROPHYLAXIS; REVIEW; TABLET FORMULATION; VOMITING;

EID: 0345731300     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0030-6665(03)00129-4     Document Type: Review

References (42)

1. Goldstein M, Chen TC. The epidemiology of disabling headache. Adv Neurol 1982:33:377-90.
2. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiat 1938;39:737-63.
3. Schumacher GA, Wolff HG. A. Contrast of histamine headache with the headache of migraine and that associated with hypertension. B. Contrast of vascular mechanisms in preheadache and in headache phenomena of migraine. Arch Neurol Psychiat 1941;45:199-214.
4. Tunis MM, Wolff HG. Long-term observations of the reactivity of the cranial arteries in subjects with vascular headache of the migraine type. Arch Neurol Psychiat 1953;70:551-7.
5. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet 1990;336:837-9.
6. De Hoon JN, Willigers JM, Troost J, et al. Cranial and peripheral interictal vascular changes in migraine patients. Cephalalgia 2003;23:96-104.
7. Chapman LF, Ramos AO, Goodell H, et al. A humoral agent implicated in vascular headache of the migraine type. Arch Neurol 1960;3:223-9.
8. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of human during migraine headache. Ann Neurol 1990;28:183-7.
9. Wolff HG, Tunis MM, Goodell H. Evidence of tissue damage and changes in pain sensitivity in subjects with vascular headaches of the migraine type. Arch Intern Med 1953;92:478-84.
10. Burnstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000;47:614-24.
11. Anselmi B, Baldi E, Casacci F, Salmon S. Endogenous opioids in cerebrospinal fluid and blood in idiopathic headache sufferers. Headache 1980;20:294-9.
12. Marcussen RM, Wolff HG. 1. Effects of carbon dioxide-oxygen mixtures given during preheadache phase of the migraine attack. 2. Further analysis of the pain mechanisms in headache. Arch Neurol Psychiat 1950;63:42-51.
13. Milner PM. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leão. Electroencephalogr Clin Neurophysiol 1958;10:705.
14. Olesen J, Friberg L, Olsen TS, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990;28:791-8.
15. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981;9:344-52.
16. Sanchez del Rio M, Bakker D, Wu O, et al. Perfusion weighted imaging during migraine: spontaneous visual aura and headache. Cephalalgia 1999;19:701-7.
17. Welch KMA, Levine SR, D'Andrea G, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 1989;39:538-41.
18. Spierings ELH. Recent advances in the understanding of migraine. Headache 1988;28:655-8.
19. Palmer JE, Chronicle EP, Rolan P, Mulleners WM. Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients. Cephalalgia 2000;20:525-32.
20. 2+ channel gene CACNL1A4. Cell 1996;87:543-52.
21. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995;1:658-60.
22. Spierings ELH, Keywood C. Clinical factors associated with low headache recurrence with frovatriptan [abstract]. Cephalalgia 2000;20:340.
23. Sheftell FD, O'Quinn S, Watson C, et al. Low migraine recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000;40:103-10.
24. Kaufman J, Levine I. Acute gastric dilatation of the stomach during attack of migraine. Radiology 1936;27:301-2.
25. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990;30:405-9.
26. Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975;2:57-63.
27. Laska EM, Sunshine A, Mueller F, et al. Caffeine as an analgesic adjuvant. JAMA 1984;251:1711-8.
28. Graham JR. Rectal use of ergotamine tartrate and caffeine alkaloid for the relief of migraine. N Engl J Med 1954;250:936-8.
29. Spierings ELH. The (suma)triptan history revisited [letter]. Headache 2000;40:766-7.
30. Spierings ELH. Optimum-dose determination of the triptans [abstract]. Headache 2000;40:433-4.
31. Spierings ELH. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan [letter]. Neurology 2000;55:735-6.
32. Tfelt-Hansen P, Aebelholt Krabbe A. Ergotamine abuse. Do patients benefit from withdrawal? Cephalalgia 1981;1:29-32.
33. Weerasuriya K, Patel L, Turner P. Beta-adrenoceptor blockade and migraine. Cephalalgia 1982;2:33-45.
34. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes, in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973;36:684-90.
35. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-9.
36. Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 1983;250:2500-2.
37. Markley HG, Cheroms JCD, Piepho RW. Verapamil in prophylactic therapy of migraine. Neurology 1984;34:973-6.
38. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-4.
39. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled cross-over study. Neurology 1994;44:647-51.
40. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6.
41. 2+ channel blockers. Eur J Pharmacol 1992;217:137-41.
42. Spierings ELH. Management of migraine. Boston (MA): Butterworth-Heinemann; 1996.